Similarly, another group showed reactivation of FMR1 in fibroblast and lymphoblastoid cell lines from patients with FXS using the hypomethylating agent chaetocin used in combination with 5‐azadeoxycytidine. The gene discussed is FMR1; the disease is fragile X syndrome.